1.
Saint-Jean A, Sainz de la Maza M, Morral M, Torras J, Quintana R, Molina JJ, et al.
Ocular adverse events of systemic inhibitors of the epidermal growth factor receptor:
report of 5 cases. Ophthalmology. 2012;119:1798-802.
2.
Marquez EB, De Ortueta D, Royo SB, Martinez-Carpio PA. Epidermal growth factor receptor
in corneal damage: update and new insights from recent reports. Cutan Ocul Toxicol.
2011;30:7-14.
3.
Babina IS, Turner NC. Advances and challenges in targeting FGFR signalling in cancer.
Nat Rev Cancer. 2017;17:318-32.
4.
Borkar DS, Lacouture ME, Basti S. Spectrum of ocular toxicities from epidermal growth
factor receptor inhibitors and their intermediate-term follow-up: a five-year review.
Support Care Cancer. 2013;21:1167-74.
5.
Raizman MB, Hamrah P, Holland EJ, Kim T, Mah FS, Rapuano CJ, et al. Drug-induced corneal
epithelial changes. Surv Ophthalmol. 2017;62:286-301.
6.
Reardon DA, Lassman AB, van den Bent M, Kumthekar P, Merrell R, Scott AM, et al. Efficacy
and safety results of ABT-414 in combination with radiation and temozolomide in newly
diagnosed glioblastoma. Neuro Oncol. 2017;19:965-75.
7.
Phillips AC, Boghaert ER, Vaidya KS, Mitten MJ, Norvell S, Falls HD, et al. ABT-414,
an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope. Mol Cancer Ther.
2016;15:661-9.
8.
Futami T, Okada H, Kihara R, Kawase T, Nakayama A, Suzuki T, et al. ASP5878, a Novel
Inhibitor of FGFR1, 2, 3, and 4, Inhibits the Growth of FGF19-Expressing Hepatocellular
Carcinoma. Mol Cancer Ther. 2017;16:68-75.
9.
Bendell JC, Rogers S, Xiang H, Pierce KL, Krishnan K, Sikorski RS, et al. FPA144-001:
A first in human study of FPA 144, an ADCC-enhanced, FGFR2b isoform-selective monoclonal
antibody in patients with advanced solid tumors. 2016;34:140-.
10.
Ahn J, Wee WR, Lee JH, Hyon JY. Vortex keratopathy in a patient receiving vandetanib
for non-small cell lung cancer. Korean J Ophthalmol. 2011;25:355-7.
11.
Zhang H. Osimertinib making a breakthrough in lung cancer targeted therapy. Onco Targets
Ther. 2016;9:5489-93.
12.
Chia PL, John T. Vortex Keratopathy Presumed Secondary to AZD9291. J Thorac Oncol.
2015;10:1807-8.
13.
D'Amico DJ, Kenyon KR. Drug-induced lipidoses of the cornea and conjunctiva. Int Ophthalmol.
1981;4:67-76.
14.
Kabir MZ, Hamzah NAB, Ghani H, Mohamad SB, Alias Z, Tayyab S. Biophysical and computational
characterization of vandetanib-lysozyme interaction. Spectrochim Acta A Mol Biomol
Spectrosc. 2018;189:485-94.
15.
Donaghy H. Effects of antibody, drug and linker on the preclinical and clinical toxicities
of antibody-drug conjugates. MAbs. 2016;8:659-71.
16.
Bouchard H, Viskov C, Garcia-Echeverria C. Antibody-drug conjugates-a new wave of
cancer drugs. Bioorg Med Chem Lett. 2014;24:5357-63.
17.
Eaton JS, Miller PE, Mannis MJ, Murphy CJ. Ocular Adverse Events Associated with Antibody-Drug
Conjugates in Human Clinical Trials. J Ocul Pharmacol Ther. 2015;31:589-604.
18.
Hossam M, Lasheen DS, Abouzid KA. Covalent EGFR Inhibitors: Binding Mechanisms, Synthetic
Approaches, and Clinical Profiles. Arch Pharm (Weinheim). 2016;349:573-93.
19.
Krachmer JHM, Mark J, Holland Cornea. 3rd ed: Mosby Elsevier 2011.
20.
van den Bent M, Gan HK, Lassman AB, Kumthekar P, Merrell R, Butowski N, et al. Efficacy
of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified,
recurrent glioblastoma: results from a multi-center, international study. Cancer Chemother
Pharmacol. 2017;80:1209-17.
21.
Lee SH, Lee JK, Ahn MJ, Kim DW, Sun JM, Keam B, et al. Vandetanib in pretreated patients
with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical
trial. Ann Oncol. 2017;28:292-7.
22.
Natale RB, Thongprasert S, Greco FA, Thomas M, Tsai CM, Sunpaweravong P, et al. Phase
III trial of vandetanib compared with erlotinib in patients with previously treated
advanced non-small-cell lung cancer. J Clin Oncol. 2011;29:1059-66.
23.
Catenacci DVT, Rha SY, Bang Y-J, Wainberg ZA, Chao J, Lee KW, et al. Updated antitumor
activity and safety of FPA144, an ADCC-enhanced, FGFR2b isoform-specific monoclonal
antibody, in patients with FGFR2b+ gastric cancer. Journal of Clinical Oncology. 2017;35:4067-.